Literature DB >> 15783115

Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis.

Ali Canoğlu1, Cağatay Göğüş, Yaşar Bedük, Diclehan Orhan, Ozden Tulunay, Sümer Baltaci.   

Abstract

INTRODUCTION: The aim of our study was to evaluate tumor angiogenesis as a prognostic marker of transitional cell carcinoma of the bladder and to asses its relationship to established variables for survival and response to therapy. PATIENTS AND
METHOD: Microvessel density (MVD), a measure of tumor angiogenesis, were evaluated in 77 primary bladder cancers. Forty-three superficial carcinomas and 34 invasive carcinomas were analysed. Tumor specimens of all patients were obtained by transurethral resection (TUR) and all the tumors were transitional cell carcinomas. Twenty-two patients with invasive bladder cancer have undergone M-VEC chemotheraphy. The correlation between MVD and histopathological grade, tumor stage and prognosis was evaluated. MVD was identified by immunostaining of endothelial cells using anti-CD34 antibody. For statistical analysis Kruskal-Vallis, Mann-Whitney U and Fisher's exact tests were used.
RESULTS: MVD was correlated with tumor grade, stage and prognosis. Significantly higher MVD was determined in invasive tumors than superficial tumors (p < 0.05). MVD increased with tumor grade and stage (p < 0.05). High MVD was correlated with the risk of clinical progression in both superficial and invasive bladder carcinomas (p < 0.05, p < 0.001 respectively). Invasive tumors with remission after M-VEC chemotheraphy had lower MVD than tumors with progression after M-VEC.
CONCLUSION: These data demonstrate that MVD in bladder carcinoma correlates with grade, stage and malignant potential of the tumor. Quantification of tumor angiogenesis may allow selection of the type of treatment for bladder cancer patients.

Entities:  

Mesh:

Year:  2004        PMID: 15783115     DOI: 10.1007/s11255-004-8869-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

Review 1.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

Review 2.  Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract.

Authors:  N Weidner
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

Review 3.  Prognostic indices in transitional cell carcinoma of the bladder.

Authors:  P D Abel
Journal:  Br J Urol       Date:  1988-08

4.  The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.

Authors:  K Inoue; J W Slaton; T Karashima; C Yoshikawa; T Shuin; P Sweeney; R Millikan; C P Dinney
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  Prognostic relevance of micro-vessel density in cancer of the urinary bladder.

Authors:  R Chaudhary; M Bromley; N W Clarke; C D Betts; R J Barnard; W D Ryder; S Kumar
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

6.  A morphometric study of neovascularization in colorectal carcinoma.

Authors:  P M Pavlopoulos; A E Konstantinidou; E Agapitos; N Kavantzas; P Nikolopoulou; P Davaris
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

7.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

8.  Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.

Authors:  G R Eure; M R Cundiff; P F Schellhammer
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

9.  Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.

Authors:  B H Bochner; D Esrig; S Groshen; M Dickinson; N Weidner; P W Nichols; D G Skinner; R J Cote
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

10.  Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.

Authors:  C P Dinney; R C Babkowski; M Antelo; P Perrotte; M Liebert; H Z Zhang; J Palmer; R W Veltri; R L Katz; H B Grossman
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  18 in total

1.  Perfusion computed tomography evaluation of angiogenesis in liver cancer.

Authors:  Han Feng Yang; Yong Du; Jia Xiang Ni; Xiang Ping Zhou; Jin Dong Li; Qing Zhang; Xiao Xue Xu; Yang Li
Journal:  Eur Radiol       Date:  2010-02-24       Impact factor: 5.315

2.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

Review 3.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

4.  The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study.

Authors:  S T Bozdoğan; B Erol; A Dursun; G Bozdoğan; I Dönmez; N A Mungan; G Seydaoglu
Journal:  World J Urol       Date:  2014-05-22       Impact factor: 4.226

Review 5.  Incorporating VEGF-targeted therapy in advanced urothelial cancer.

Authors:  Sujata Narayanan; Sandy Srinivas
Journal:  Ther Adv Med Oncol       Date:  2016-09-16       Impact factor: 8.168

Review 6.  VEGF inhibition in urothelial cancer: the past, present and future.

Authors:  Sanaz Ghafouri; Aaron Burkenroad; Morgan Pantuck; Bara Almomani; Dimitris Stefanoudakis; John Shen; Alexandra Drakaki
Journal:  World J Urol       Date:  2020-05-02       Impact factor: 4.226

7.  Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.

Authors:  Farha A El-Chennawi; Fatma A Auf; Shereen S Metwally; Youssef M Mosaad; Atallah A Shaaban; Mahmoud Abdo El-Baz; Ziyad E Tawhid; Zakaria F Lotfy
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

Review 8.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Chi Lam Au Yeung; Stephen T C Wong; Samuel C Mok
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-29       Impact factor: 4.249

Review 9.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 10.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.